Medical Reserch and Education ›› 2019, Vol. 36 ›› Issue (1): 6-12.DOI: 10.3969/j.issn.1674-490X.2019.01.002

Previous Articles     Next Articles

  

  • Received:2018-12-24 Online:2019-02-25 Published:2019-02-25

Abstract: Toll-like receptors(TLRs)are critical regulators of innate immunity and inflammatory response in cerebral ischemic injury. In recent years, with a deeper understanding of the signaling mechanisms of TLRs during the onset of stroke, targeting TLRs have become a promising therapy for cerebral ischemic stroke. Medication or compounds can inhibit the inflammatory reaction in cerebral ischemia via directly acting on TLRs, modulating MyD88 or TRIF signaling pathways, and TLRs ligand preconditioning or postconditioning. This review will focus on promising therapies which exert neuroprotective effects against ischemic injury by acting on TLRs.

Key words: cerebral ischemia, Toll-like receptors, medication, inflammation

CLC Number: